The FDA has approved canagliflozin (Invokana) to reduce the risk of major adverse cardiovascular events (MACE) including stroke, heart attack and cardiac death in patients with type 2 diabetes and established cardiovascular disease. It is the first oral diabetes medication to gain this indication, according to drug manufacturer Janssen Pharmaceutical Companies.

Evolocumab appears to be equally effective at reducing LDL cholesterol and preventing cardiovascular events regardless of a patient’s kidney function, according to a new subanalysis of the FOURIER outcomes study presented at the American Society of Nephrology’s annual Kidney Week in San Diego.

Overweight and obese women might face better odds against diabetes, insulin resistance and CVD than men, according to a rodent study out of York University in Toronto.

Managing their high blood pressure is the best way patients with diabetes can avoid hypertensive emergencies, according to research published in Clinical and Experimental Hypertension this fall.

A free phone app helped a low-income, obese patient population achieve clinically meaningful weight loss, researchers from Duke University reported in the American Journal of Preventive Medicine.

Having reduced cardiorespiratory fitness (CRF) is as harmful to survival as coronary artery disease, smoking cigarettes or diabetes, suggests a retrospective study published Oct. 19 in JAMA Network Open.

Good oral health—in particular a lack of periodontal disease—has been linked to lower systolic blood pressure and a better chance at successful antihypertensive therapy in patients with high BP, according to research published Oct. 22 in Hypertension.

Bariatric surgery may help reduce cardiovascular events beyond normal treatment with medication and lifestyle modifications for patients with severe obesity and type 2 diabetes, suggests an observational study published in JAMA.